Literature DB >> 17451772

Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase.

Marleen C D G Huigen1, Loek de Graaf, Dirk Eggink, Rob Schuurman, Viktor Müller, Anna Stamp, David K Stammers, Charles A B Boucher, Monique Nijhuis.   

Abstract

HIV-1 isolates harbouring an insertion in the beta3-beta4 loop of reverse transcriptase (RT) confer high-level resistance to nucleoside analogues. We have identified a novel 5-amino-acid insertion (KGSNR amino acids 66-70) in a patient on prolonged nucleoside combination therapy (didanosine and stavudine) and investigated which factors were responsible for its outgrowth. Remarkably, only small fold increases in drug resistance to nucleoside analogues were observed compared to wild type. The insertion variant displayed a reduced replicative capacity in the absence of inhibitor, but had a slight replicative advantage in the presence of zidovudine, didanosine or stavudine, resulting in the selection and persistence of this insertion in vivo. Mathematical analyses of longitudinal samples indicated a 2% in vivo fitness advantage for the insertion variant compared to the initial viral population. The novel RT insertion variant conferring low levels of resistance was able to evolve towards a high-level resistant replication-competent variant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451772     DOI: 10.1016/j.virol.2007.03.028

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  3 in total

1.  Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations.

Authors:  Shanmugam Saravanan; Vidya Madhavan; Rami Kantor; Sathasivam Sivamalar; Selvamurthi Gomathi; Sunil S Solomon; Nagalingeswaran Kumarasamy; Davey M Smith; Robert T Schooley; Suniti Solomon; Pachamuthu Balakrishnan
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-21       Impact factor: 2.205

2.  Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.

Authors:  Noortje M van Maarseveen; Annemarie Mj Wensing; Dorien de Jong; Greg L Beilhartz; Aleksandr Obikhod; Sijia Tao; Marieke Pingen; Joop E Arends; Andy Im Hoepelman; Raymond F Schinazi; Matthias Götte; Monique Nijhuis
Journal:  Antivir Ther       Date:  2011

Review 3.  The remarkable frequency of human immunodeficiency virus type 1 genetic recombination.

Authors:  Adewunmi Onafuwa-Nuga; Alice Telesnitsky
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.